Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume

Lidija Milicic · Michael Vacher · Tenielle Porter · Vincent Doré · Samantha C. Burnham · Pierrick Bourgeat · Rosita Shishegar · James Doecke · Nicola J. Armstrong · Rick Tankard · Paul Maruff · Colin L. Masters · Christopher C. Rowe · Victor L. Villemagne · Simon M. Laws · Alzheimer’s Disease Neuroimaging Initiative (ADNI) · Australian Imaging Biomarkers and Lifestyle (AIBL) Study

Received: 7 February 2022 / Accepted: 30 March 2022 / Published online: 21 April 2022

Abstract The concept of age acceleration, the difference between biological age and chronological age, is of growing interest, particularly with respect to age-related disorders, such as Alzheimer’s Disease (AD). Whilst studies have reported associations with AD risk and related phenotypes, there remains a lack of consensus on these associations. Here we aimed to comprehensively investigate the relationship between five recognised measures of age acceleration, based on DNA methylation patterns (DNAm age), and cross-sectional and longitudinal cognition and AD-related neuroimaging phenotypes (volumetric MRI and Amyloid-β PET) in the Australian Imaging, Biomarkers and Lifestyle (AIBL) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Significant associations were observed between age acceleration using the Hannum epigenetic clock and cross-sectional hippocampal volume in AIBL and replicated in ADNI. In AIBL, several other findings were observed cross-sectionally, including a significant association

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11357-022-00558-8.

© The Author(s) 2022

Lists of investigators and their affiliations appear at the end of the paper.
between hippocampal volume and the Hannum and Phenoage epigenetic clocks. Further, significant associations were also observed between hippocampal volume and the Zhang and Phenoage epigenetic clocks within Amyloid-β positive individuals. However, these were not validated within the ADNI cohort. No associations between age acceleration and other Alzheimer’s disease-related phenotypes, including measures of cognition or brain Amyloid-β burden, were observed, and there was no association with longitudinal change in any phenotype. This study presents a link between age acceleration, as determined using DNA methylation, and hippocampal volume that was statistically significant across two highly characterised cohorts. The results presented in this study contribute to a growing literature that supports the role of epigenetic modifications in ageing and AD-related phenotypes.

**Keywords**  DNA methylation · Epigenetics · Alzheimer’s disease · Hippocampal volume · Cognition · Ageing

**Abbreviations**

AD  Alzheimer’s disease  
DNAm age  DNA methylation age  
AIBL  Australian Imaging Biomarkers and Lifestyle  
ADNI  Alzheimer’s Disease Neuroimaging Initiative  
Aβ  Amyloid-β  
a-DMRs  Ageing-associated differentially methylated regions

---

N. Armstrong  
Department of Mathematics and Statistics, Curtin University, Bentley, Western Australia, Australia

R. Tankard  
School of Mathematics and Statistics, Murdoch University, Perth, Western Australia, Australia

P. Maruff · C. Masters · C. Rowe  
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3052, Australia

P. Maruff  
Cogstate Ltd, Melbourne, VIC, Australia

V. Villemagne  
Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA

---

**Introduction**

Biological ageing, which affects most living organisms, can be characterised by a gradual loss of physical integrity, leading to impaired function and increased susceptibility to age-related disease and, ultimately, death [1]. Ageing is driven by genetic factors and external events, such as lifestyle, environment and their interaction [2]. Age is regarded as the most important non-modifiable risk factor for all neurodegenerative diseases, including Alzheimer’s disease (AD), and has been associated with changes in DNA methylation patterns [3].

Age-associated deregulation of the epigenome is a hallmark of the ageing process and has been studied extensively in recent years, which has resulted in evidence suggesting that changes in epigenetic patterns are dynamic through entire lifetimes in all species, tissues and cell types [4].
The ageing process leads to changes in DNA methylation patterns throughout the genome, and this has been termed epigenetic drift. Such changes result in genome wide hypomethylation and site-wide hypermethylation [2]. Epigenetic drift is unpredictable as it involves non-directional changes of both hypomethylation and hypermethylation of DNA. This limits any prediction of changes in the methylome amongst ageing individuals [2]. However, some evidence points towards the existence of ageing-associated differentially methylated regions (a-DMRs), which are consecutive groups of cytosine-phosphate-guanine (CpG) dinucleotides, sites that exhibit change in a constant direction over time [5–7]. Thus, methylation changes may not be purely stochastic but may also be associated with biological mechanisms closely linked to ageing processes and longevity.

DNA methylation clocks, also commonly referred to as epigenetic clocks, are DNA methylation-based estimates of biological age, which are developed through the combined use of mathematical algorithms and sets of CpGs that are strongly correlated with age ($r \geq 0.8$) [8]. In 2011, Bocklandt et al. [9] developed an epigenetic clock that is able to predict chronological age in years, using peripheral blood with an average error of 5.2 years, based on 2 CpG sites present on the Illumina 27 k array. Of the epigenetic clocks developed since, the Hannum clock [10] was trained on blood derived DNA and comprises 71 CpG sites selected from the Illumina 450 k array, and the Horvath clock [11], developed around the same time, was constructed using multiple tissues and was intended to capture age-related changes, independent of tissue type. The Horvath clock is composed of 353 CpG sites that are all present on the earliest generation Illumina 27 k array [11]. Subsequently, Zhang and colleagues [12] developed two clocks based on two different training methods—best linear unbiased prediction (BLUP) and elastic net (EN). These two clocks were trained on a very large sample size of 13,661 samples, composed primarily of peripheral blood (13,402 samples) and saliva (259 samples). These clocks comprise 319,607 and 514 CpG sites, respectively, present on the Illumina 450 k and Illumina EPIC arrays. The second generation PhenAge clock, developed by Levine and colleagues [13], is an epigenetic predictor of phenotypic age, a better representative than chronological age, of age-related biological dysregulation, derived from measures of clinical biomarkers. This difference led to substantial improvements in prediction of mortality and health span (number of years lived disease-free) compared to first generation clocks by Hannum and Horvath. The PhenAge clock was trained on blood derived DNA and comprises 513 CpG sites [13] and captures multifactorial ageing conditions, which is consistent with the fundamental underpinnings of ageing research.

Chronological age, defined as an individual’s legal age as calculated from birth to the current date, is not always an accurate indicator of the biological process of ageing, which makes it difficult to evaluate measures that promote longevity and healthy ageing [14]. Consequently, biological age has been proposed as a method to accurately predict the ageing status of an individual or tissue and could be reliably used to predict the onset of multiple diseases, assess disease risk and aid in the development of preventative strategies [14]. Since peripheral blood is easily accessible and largely non-invasive, it is suitable for multiple, repeated sampling over long periods of time, such as annual doctors’ visits, allowing for age or disease-related changes to be captured relatively early in the disease process and for appropriate preventative strategies based on the epigenetic evidence, to be put in place. Similarly, since obtaining samples is relatively non-invasive, multiple samples can be obtained during lifestyle interventions or drug trials, allowing response to treatment or intervention to be monitored easily and inexpensively, especially when compared to imaging modalities commonly used, such as magnetic resonance imaging (MRI) and positron emission topography (PET).

A measure of age acceleration (or deceleration) can be calculated based on the difference between an individual’s biological age (estimated through the use of epigenetic clocks) and chronological age (an individual’s legal age) [15]. Accelerated ageing has been documented in several genetic syndromes such as Down syndrome [16] and Werner’s syndrome [17]. Additionally, premature ageing in HIV infected individuals [18, 19] has been observed as well as in individuals with a high body mass index (BMI) and metabolic diseases [20]. As well, there is evidence for accelerated ageing in neurodegenerative diseases such as Parkinson’s disease [21], Huntington’s disease [22] and AD [15]. DNA
methylation, both hyper- and hypomethylation, has been associated with AD in several brain regions [23–27]; however, it is still largely unclear whether markers in peripheral blood are truly reflective of the same changes as those observed in the brain [28]. In studies measuring DNA methylation age (DNAm age), accelerated ageing has been linked to an increase in AD pathology (diffuse plaques, neurotic plaques and Amyloid-β (Aβ) burden) [29], and in studies utilising peripheral DNAm age, accelerated ageing has been associated with reduced cognitive and physical fitness and an increase in all-cause mortality [15]. Whilst there is some evidence that accelerated ageing is associated with AD-related pathology and cognition, there is also conflicting research which does not support this. For example, Starnawska and colleagues [30] found that DNAm age is not associated with cognition in middle-age monozygotic twins and in a cohort of 964 middle-aged adults; Belsky et al. [31] also found no associations between DNAm age and cognition. However, it is difficult to compare results of studies as each utilised a different clock methodology to generate age estimates. Starnawska et al. [30] used the Hannum and Horvath clocks, and Belsky [31] used telomere length, the Klemera-Doubal method and pace of ageing clocks. Further, since the field is rapidly expanding and new clocks are being developed, consideration must be put into clock choice depending on the cohort and data available. Based on the inconsistency of results and the paucity of literature clearly describing the association of DNAm age and AD-related phenotypes, we set out to test the hypothesis that accelerated ageing is associated with differences in AD-related phenotypes. Using the highly characterised prospective longitudinal Australian Imaging, Biomarkers and Lifestyle (AIBL) study cohort we aimed to comprehensively investigate several methods of assessing DNAm age to assess (1) whether accelerated ageing is associated with cross-sectional measures of cognition and AD-related neuroimaging phenotypes (volumetric MRI and Aβ-PET) and (2) whether an individual’s current DNAm age is a predictor of future longitudinal changes in these two phenotypes. We then sought to test the robustness of our findings through validation within a similar highly characterised longitudinal cohort, the Alzheimer’s Disease Neuroimaging Initiative (ADNI).

### Materials and methods

#### Participants

This study included participants enrolled in both the ongoing prospective longitudinal Australian Imaging, Biomarkers and Lifestyle and the multi-centre, longitudinal Alzheimer’s Disease Neuroimaging Initiative cohort studies. Detailed descriptions of both AIBL [32, 33] and ADNI [34] have been published previously. Participants enrolled in AIBL or ADNI were selected for inclusion in the current study only if methylation data and longitudinal (>3 timepoints) data was available for the respective phenotype analysed (i.e. PET imaging and MRI or cognition).

#### Neuroimaging and cognitive data

Individuals within the AIBL cohort underwent brain Aβ imaging by positron emission tomography (PET) using one of three tracers: $^{11}$C–Pittsburgh compound B (PiB), $^{18}$F-florbetapir or $^{18}$F-flutemetamol. Of these, 373 had >3 timepoints and were included in this study. Similarly, ADNI participants underwent Aβ PET imaging studies with either $^{18}$F-florbetaben or $^{18}$F-florbetapir, with 486 participants included for validation purposes. In both cohorts, resulting Aβ PET scans were analysed using the CapAIBL software [35], an open access, web-based magnetic resonance (MR)-less algorithm, to generate standardised uptake value (SUV) ratios (SUVR) for all tracers and their associated. These tracer specific SUVR levels were then transformed and expressed in centiloid values (CL) as described previously [36, 37]. Aβ PET status was considered as Aβ negative (Aβ−; <20 CL) or Aβ positive (Aβ+; ≥20 CL).

Of the 373 AIBL participants included in this study, 329 also had available MRI data, whilst 382 of the included ADNI participants underwent an MRI scan. MRI images were obtained at 3 T using the ADNI T1 magnetisation-prepared rapid gradient echo (MPRAGE) protocol with subsequent estimation of all cortical volumes from the T1 using Freesurfer, as previously described [13]. All volumes were corrected for normal ageing and ICV, with left and right volumes averaged. Volumetric corrections were made using a regression-based approach against a reference population that included ‘super’ healthy subjects, being cognitively unimpaired (MMSE >28, CDR =0)
Ab negative individuals who did not carry an Apolipoprotein E (APOE) ε4 allele.

Both AIBL and ADNI participants undertook comprehensive neuropsychological assessment as previously described [32–34]. The resulting test scores were used for the calculation of the pre-Alzheimer’s cognitive composite (PACC), in AIBL, as described by Donohue et al. [38] and a modified PACC for ADNI [39]. This data was available at >3 timepoints for 358 (out of 373) and 469 (out of 486) individuals from AIBL and ADNI, respectively.

Genetic and epigenetic data

AIBL and ADNI study participant DNA was isolated for downstream analysis from whole blood using QIAamp DNA blood spin column kits (Qiagen, Valencia, CA, USA) as described previously [32–34]. Likewise, APOE genotyping protocols for AIBL and ADNI have been published previously [40, 41]. APOE carrier status was defined as the presence (one or two copies of the APOE ε4 allele) or absence (zero copies of the APOE ε4 allele).

DNA methylation analysis was conducted as previously described [41, 42]. Briefly, DNA samples were bisulphite converted using EZ DNA Methylation Kits (Zymo Research, Orange, CA, USA), and genome-wide DNA methylation patterns were analysed using the Infinium HumanMethylation EPIC (850 k) BeadChip array (Illumina, Inc., San Diego, CA, USA). BeadChips were washed, labelled using single-base extension, stained with multiple layers of fluorescence and scanned using the Illumina iScan system (Illumina Inc, CA). QC and normalisation of generated DNA methylation data were undertaken using the meffil package in R [43] (Version 3.5.0.) as previously described [41, 42]. Samples that failed QC were excluded from further analysis.

Estimation of DNA methylation age

Five clock methodologies (Horvath [11], Hannum [10], Phenoage [13], Zhang elastic net (EN) and Zhang best linear unbiased prediction (BLUP)) [12] were utilised to calculate age estimates (DNAm age) for all AIBL (n=373) and ADNI (n=486) samples. Each clock is composed of a unique, defined set of CpG sites whose DNA methylation levels are used to generate an estimate of DNAm age. The CpG sites used in the calculation of each clock were chosen based on the statistical methodology specific to each clock [10–13]. In the current study, we utilised both disproportionate biological age (DBAge), which is the residual from regressing biological age on chronological age [29], and difference in age (DiffAge) [44], calculated by subtracting chronological age from biological age, as measures of age acceleration/deceleration. Both methodologies for calculating deviations in biological age from chronological age are a widely used and accepted methods to quantify ageing [44, 45]. The difference between DBAge and DiffAge is that the latter is a relative measure representing the difference between chronological age and biological age at the individual level, irrespective of other samples, whereas DBAge measures the difference between an individual’s DNAm age and the predicted DNAm age for that individual’s chronological age based on all samples present in the cohort. Thus, DiffAge measures the degree of ageing when compared to all other samples in the cohort. Here, we present only DBAge results as DiffAge and DBAge results were highly correlated in both the AIBL (Horvath $R^2=0.92$; Zhang BLUP $R^2=0.97$; Zhang EN $R^2=0.94$; Phenoage $R^2=0.98$; Supplementary Fig. 1, Additional File 1) and ADNI (Horvath $R^2=0.96$; Zhang BLUP $R^2=1.00$; Zhang EN $R^2=0.96$, Phenoage $R^2=0.99$; Supplementary Fig. 2, Additional File 1) cohorts. DiffAge results can be found in Additional file 1.

Statistical analysis

Statistical analyses were carried out in R Version 4.1.2 for Macintosh. Baseline demographic data analyses provided means, standard deviations and percentages across the whole cohort and by confirmed classifications of cognitively unimpaired (CU), mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Analysis of variance (ANOVA; age) and chi-squared tests (gender, years of education, APOE ε4+ve, high Aβ burden, smoking status) were used to determine the significance of differences between groups. These demographic and clinical characteristics are summarised in Table 1. For all analyses described below, analyses were first undertaken in the AIBL sample, with associations surviving correction for false discovery rate (FDR) [46] subsequently tested in the ADNI sample.

To determine whether accelerated age is associated with cross-sectional measures of cognition (the pre-Alzheimer’s cognitive composite (PACC)) and
| AIBL            | Whole cohort | Cognitively unimpaired | Mild cognitive impairment | Alzheimer’s disease | p     |
|----------------|-------------|------------------------|--------------------------|---------------------|-------|
| n=373          | n=240       | n=69                   | n=64                     |                     |       |
| Age, mean (SD) | 73.43 (6.99)| 72.44 (6.42)           | 74.96 (7.58)             | 75.52 (7.74)        | 0.0003|
| Female n (%)   | 197 (52.8)  | 137 (57.1)             | 26 (37.7)                | 34 (53.1)           | 0.017 |
| Years of education n (%) |       |                        |                          |                     |       |
| 0–8            | 32 (8.57)   | 13 (5.4)               | 10 (14.5)                | 9 (14.1)            | 0.077 |
| 9–12           | 155 (41.55) | 100 (41.7)             | 32 (46.4)                | 23 (35.9)           |       |
| 13–15          | 75 (21.10)  | 53 (22.1)              | 9 (13.0)                 | 13 (20.3)           |       |
| 15+            | 108 (28.95) | 73 (30.4)              | 18 (26.1)                | 17 (26.6)           |       |
| APOE ε4 carriage n (%) | 160 (42.89) | 77 (32.08)             | 34 (49.27)               | 49 (76.56)          | 3.254e−09 |
| Aβ+ n (%)      | 171 (45.84) | 72 (30)                | 42 (60.86)               | 57 (89.06)          | 2.2e−16|
| MRI n (%)      | 329 (88.2)  | 220 (91.66)            | 57 (82.60)               | 52 (81.25)          | 0.485 |
| Smoking status n (%) |       |                        |                          |                     |       |
| 0–8            | 32 (8.57)   | 13 (5.4)               | 10 (14.5)                | 9 (14.1)            | 0.077 |
| 9–12           | 155 (41.55) | 100 (41.7)             | 32 (46.4)                | 23 (35.9)           |       |
| 13–15          | 75 (21.10)  | 53 (22.1)              | 9 (13.0)                 | 13 (20.3)           |       |
| 15+            | 108 (28.95) | 73 (30.4)              | 18 (26.1)                | 17 (26.6)           |       |
| APOE ε4 carriage n (%) | 160 (42.89) | 77 (32.08)             | 34 (49.27)               | 49 (76.56)          | 3.254e−09 |
| Aβ+ n (%)      | 171 (45.84) | 72 (30)                | 42 (60.86)               | 57 (89.06)          | 2.2e−16|
| MRI n (%)      | 329 (88.2)  | 220 (91.66)            | 57 (82.60)               | 52 (81.25)          | 0.485 |
| Smoking status n (%) |       |                        |                          |                     |       |
| 0–8            | 32 (8.57)   | 13 (5.4)               | 10 (14.5)                | 9 (14.1)            | 0.077 |
| 9–12           | 155 (41.55) | 100 (41.7)             | 32 (46.4)                | 23 (35.9)           |       |
| 13–15          | 75 (21.10)  | 53 (22.1)              | 9 (13.0)                 | 13 (20.3)           |       |
| 15+            | 108 (28.95) | 73 (30.4)              | 18 (26.1)                | 17 (26.6)           |       |

| ADNI            | Whole cohort | Cognitively unimpaired | Mild cognitive impairment | Alzheimer’s disease | p     |
|----------------|-------------|------------------------|--------------------------|---------------------|-------|
| n=486          | n=166       | n=256                  | n=64                     |                     |       |
| Age, mean (SD) | 73.92 (7.51)| 75.91 (6.71)           | 72.05 (7.46)             | 76.26 (7.84)        | 0.09  |
| Female n (%)   | 227 (46.70)| 86 (51.80)             | 115 (44.92)              | 26 (40.62)          | 0.22  |
| Years of education n (%) |       |                        |                          |                     |       |
| 0–8            | 4 (0.8)     | 2 (1.20)               | 1 (0.40)                 | 1 (1.60)            | 0.90  |
| 9–12           | 60 (12.30)  | 18 (10.84)             | 34 (13.28)               | 8 (12.50)           |       |
| 13–15          | 89 (18.3)   | 31 (18.67)             | 45 (17.57)               | 13 (20.31)          |       |
| 15+            | 333 (68.5)  | 115 (69.27)            | 176 (68.75)              | 42 (65.62)          |       |
| APOE ε4 carriage n (%) | 204 (41.97) | 44 (26.50)             | 114 (44.53)              | 66 (71.87)          | 1.615e−09 |
| Aβ+ n (%)      | 250 (51.4)  | 51 (30.72)             | 143 (55.85)              | 56 (87.50)          | 1.372e−14|
| MRI n (%)      | 382 (78.60) | 117 (79.48)            | 229 (89.45)              | 36 (56.25)          | 0.47  |
| Smoking status n (%) |       |                        |                          |                     |       |
| 0–8            | 4 (0.8)     | 2 (1.20)               | 1 (0.40)                 | 1 (1.60)            | 0.90  |
| 9–12           | 60 (12.30)  | 18 (10.84)             | 34 (13.28)               | 8 (12.50)           |       |
| 13–15          | 89 (18.3)   | 31 (18.67)             | 45 (17.57)               | 13 (20.31)          |       |
| 15+            | 333 (68.5)  | 115 (69.27)            | 176 (68.75)              | 42 (65.62)          |       |
| APOE ε4 carriage n (%) | 204 (41.97) | 44 (26.50)             | 114 (44.53)              | 66 (71.87)          | 1.615e−09 |
| Aβ+ n (%)      | 250 (51.4)  | 51 (30.72)             | 143 (55.85)              | 56 (87.50)          | 1.372e−14|
| MRI n (%)      | 382 (78.60) | 117 (79.48)            | 229 (89.45)              | 36 (56.25)          | 0.47  |

Baseline demographic and clinical characteristics of all participants with available methylation data in the AIBL study. p values represent significance when comparing between classifications.

Aβ+ high Aβ burden, MRI magnetic resonance imaging, APOE ε4 apolipoprotein ε4 allele, PACC pre-Alzheimer’s cognitive composite
neuroimaging phenotypes (grey and white matter volume, hippocampal volume, ventricle volume and Aβ burden) in the brain, linear regressions were utilised. Phenotype outcomes (cognition and neuroimaging phenotypes) were set as the dependent variables, and the measures of methylation age estimates set as the independent variables. APOE ε4 (absence/presence), sex (binary), age (years), years of education (categorical) and smoking status [47] (binary) were included as covariates. The most appropriate model to fit the data was defined using a stepwise selection based on the Akaike information criterion (AIC) [48]; this model was defined as below:

\[
\text{Phenotype} \sim \text{DiffAge OR DBAge} + \text{Age} + \text{Sex} + \text{APOE}^\varepsilon4 + \text{Years of education} + \text{Smoking Status}
\]

To determine whether an individual’s current DBAge or DiffAge is an indicator of longitudinal change in cognition and neuroimaging phenotypes, linear regressions were utilised with FDR correction. Here, we calculated the rate of change in the outcome of interest (cognition and each neuroimaging phenotype), in individuals with at least three timepoints of assessments, using linear regressions to estimate individual model slopes. The slope value was then used as the dependent variable in subsequent analyses, with the model intercept included as a covariate, in addition to APOE ε4 (absence/presence), sex (binary), age (years), years of education (categorical) and smoking status (binary). As with previous model selection, the model with the best fit was chosen using the AIC and was defined as below:

\[
\text{Slope} \sim \text{DiffAge OR DBAge residual} + \text{Intercept} + \text{Age} + \text{Sex} + \text{APOE}^\varepsilon4 + \text{Years of education} + \text{Smoking Status}
\]

**Results**

Demographic data for the AIBL and ADNI imaged cohorts and clinical classification (CU, MCI and AD) with available methylation data are presented in Table 1. This study assessed 373 AIBL participants (CU=240, MCI=60 and AD=64), aged 73.43±6.99 years with 197 females at baseline, and 486 ADNI participants (CU=166, MCI=256, AD=64), aged 73.9±7.51 years with 227 females at baseline. In the AIBL cohort, significant differences were observed when comparing age across clinical classifications (\(p=0.0003\), sex \((p=0.017)\), APOE ε4 allele carriage \((p=3.254e-09)\) and high Aβ burden \((p=2.2e-16)\). In the ADNI cohort, significant differences were observed when comparing APOE ε4 allele carriage \((p=1.615e-09)\) and high Aβ burden \((p=1.372e-14)\).

Accelerated biological ageing is not associated with cross-section and longitudinal measures of cognition

In the cognitively unimpaired Aβ+ cohort, a nominally significant association between cross-sectional PACC scores and accelerated ageing was observed with the Phenoage clock (Supplementary Table 1, Additional File 1). In the cognitively unimpaired Aβ− cohort, a nominally significant association between cross-sectional PACC scores and accelerated ageing was observed with the Horvath clock (Supplementary Table 1, Additional File 1). These associations did not remain significant after FDR correction. In the whole cohort, nominally significant associations were observed between change in PACC performance and accelerated ageing, using the Hannum clock (Supplementary Table 6, Additional File 1). In the Aβ+ cohort, nominally significant associations were observed between change in PACC performance and accelerated ageing, using the Hannum clock (Supplementary Table 6, Additional File 1). These associations did not remain significant after FDR correction.

Accelerated biological ageing is not associated with cross-section and longitudinal measures of Aβ burden

No significant associations were observed between measures of age acceleration and Aβ burden, cross-sectionally, or longitudinally in the AIBL sample (Supplementary Tables 2 and 7, Additional File 1).

Accelerated biological ageing is associated with cross-sectional measures of brain volume

In the whole cohort, nominally significant associations between hippocampal volume and accelerated ageing were observed with the Hannum and Phenoage clocks and between ventricle volume and the Hannum clock (Table 2). In the Aβ+ cohort,
nominally significant associations between hippocampal volume and accelerated ageing were observed with the Zhang EN, Hannum and Phenoage clocks (Table 2). In the Aβ+ cohort, nominally significant associations between hippocampal volume and accelerated ageing were observed with the Hannum clock (Table 2). After FDR correction, in the whole cohort, two associations remained significant, being associations between accelerated ageing and hippocampal volume using the Hannum clock (estimate $= -0.029$, $SE = 0.009$, CI $= -0.047$ to $-0.110$, 0.007.}

---

**Table 2 AIBL cross-sectional hippocampal volume**

| Population (n)         | Predictor   | Estimate | SE  | CI 95      | P predictor |
|------------------------|-------------|----------|-----|------------|-------------|
| Whole cohort (329)     | Zhang EN    | $-0.021$ | 0.013 | $-0.047$ to $-0.005$ | 0.149       |
|                        | Zhang BLUP  | $-0.009$ | 0.013 | $-0.034$ to $-0.016$ | 0.471       |
|                        | Hannum      | $-0.029$ | 0.009 | $-0.047$ to $-0.11$  | 0.007       |
|                        | Horvath     | $-0.012$ | 0.008 | $-0.027$ to $-0.003$ | 0.149       |
|                        | Phenoage    | $-0.019$ | 0.006 | $-0.031$ to $-0.006$ | 0.009**     |
| Aβ+ (145)              | Zhang EN    | $-0.050$ | 0.021 | $-0.092$ to $-0.008$ | 0.032**     |
|                        | Zhang BLUP  | $-0.030$ | 0.020 | $-0.070$ to $-0.010$ | 0.136       |
|                        | Hannum      | $-0.045$ | 0.014 | $-0.072$ to $-0.018$ | 0.003**     |
|                        | Horvath     | $-0.020$ | 0.011 | $-0.041$ to $-0.002$ | 0.097       |
|                        | Phenoage    | $-0.034$ | 0.010 | $-0.054$ to $-0.015$ | 0.003**     |
| Aβ− (184)              | Zhang EN    | 0.002    | 0.015 | $-0.028$ to $-0.032$ | 0.875       |
|                        | Zhang BLUP  | 0.014    | 0.015 | $-0.016$ to $-0.044$ | 0.875       |
|                        | Hannum      | $-0.009$ | 0.011 | $-0.031$ to $-0.014$ | 0.875       |
|                        | Horvath     | 0.002    | 0.010 | $-0.017$ to $-0.022$ | 0.875       |
|                        | Phenoage    | 0.002    | 0.008 | $-0.014$ to $-0.017$ | 0.875       |
| Cognitively unimpaired (220) | Zhang EN | $-0.014$ | 0.014 | $-0.041$ to $-0.013$ | 0.507       |
|                        | Zhang BLUP  | $-0.001$ | 0.014 | $-0.028$ to $-0.025$ | 0.921       |
|                        | Hannum      | $-0.024$ | 0.010 | $-0.044$ to $-0.004$ | 0.999       |
|                        | Horvath     | $-0.001$ | 0.009 | $-0.019$ to $-0.016$ | 0.921       |
|                        | Phenoage    | $-0.010$ | 0.007 | $-0.024$ to $-0.004$ | 0.414       |
| Cognitively unimpaired Aβ+ (65) | Zhang EN | $-0.069$ | 0.025 | $-0.120$ to $-0.019$ | 0.019**     |
|                        | Zhang BLUP  | $-0.034$ | 0.024 | $-0.082$ to $-0.015$ | 0.209       |
|                        | Hannum      | $-0.058$ | 0.019 | $-0.096$ to $-0.020$ | 0.018**     |
|                        | Horvath     | $-0.013$ | 0.018 | $-0.049$ to $-0.023$ | 0.483       |
|                        | Phenoage    | $-0.038$ | 0.016 | $-0.069$ to $-0.007$ | 0.030**     |
| Cognitively unimpaired Aβ− (155) | Zhang EN | 0.004    | 0.016 | $-0.029$ to $-0.036$ | 0.828       |
|                        | Zhang BLUP  | 0.014    | 0.017 | $-0.019$ to $-0.047$ | 0.828       |
|                        | Hannum      | $-0.015$ | 0.012 | $-0.039$ to $-0.010$ | 0.828       |
|                        | Horvath     | 0.004    | 0.011 | $-0.017$ to $-0.026$ | 0.828       |
|                        | Phenoage    | $-0.004$ | 0.008 | $-0.020$ to $-0.012$ | 0.828       |

AIBL cross-sectional results for associations between accelerated ageing (DBAge) and hippocampal volume. $p$ values shown represent values after FDR correction. Bolded values with ** represent values that remain significant after FDR correction.

$SE$ standard error, CI 95 95% confidence intervals, $P$ predictor $p$ value of clock used, EN elastic net BLUP best linear unbiased prediction, Aβ Amyloid-β
After FDR correction, in the Aβ+ cohort, associations between hippocampal volume and accelerated ageing using the Zhang EN (estimate = −0.050, SE = 0.021, CI = −0.092–−0.008, p = 0.032, Table 2), Hannum (estimate = −0.045, SE = 0.014, CI = −0.072–−0.018, p = 0.003; Table 2) and Phenoage (estimate = −0.034, SE = 0.010, CI = −0.054–−0.015, p = 0.003; Table 2), clocks remained significant. In the cognitively unimpaired Aβ+ cohort, associations between hippocampal volume and accelerated ageing using the Zhang EN (estimate = −0.069, SE = 0.025, CI = −0.120–−0.019, p = 0.019; Table 2), Hannum (estimate = −0.058, SE = 0.019, CI = −0.096–−0.020, p = 0.018; Table 2) and Phenoage (estimate = −0.038, SE = 0.016, CI = −0.069–−0.007, p = 0.030; Table 2), clocks remained significant. This finding was validated within ADNI, in the cognitively unimpaired Aβ+ cohort, where a significant association

| Population (n) | Predictor | Estimate | SE  | CI 95          | P predictor |
|---------------|-----------|----------|-----|----------------|-------------|
| Whole cohort (382) | Zhang EN  | −0.004   | 0.006 | −0.016–−0.007 | 0.482       |
|                | Zhang BLUP | −0.004   | 0.006 | −0.015–−0.007 | 0.445       |
|                | Hannum    | −0.002   | 0.004 | −0.011–−0.006 | 0.602       |
|                | Horvath   | −0.003   | 0.004 | −0.010–−0.004 | 0.425       |
|                | Phenoage  | −0.003   | 0.003 | −0.010–−0.003 | 0.344       |
| Aβ+ (194)      | Zhang EN  | −0.007   | 0.009 | −0.025–−0.010 | 0.392       |
|                | Zhang BLUP | −0.006   | 0.008 | −0.022–−0.010 | 0.428       |
|                | Hannum    | −0.005   | 0.006 | −0.017–−0.006 | 0.371       |
|                | Horvath   | −0.006   | 0.005 | −0.016–−0.003 | 0.193       |
|                | Phenoage  | −0.007   | 0.005 | −0.016–−0.002 | 0.146       |
| Aβ− (188)      | Zhang EN  | −0.001   | 0.008 | −0.017–−0.015 | 0.866       |
|                | Hannum    | 0.005    | 0.006 | −0.008–−0.017 | 0.471       |
|                | Horvath   | 0.000    | 0.005 | −0.010–−0.011 | 0.955       |
|                | Phenoage  | 0.002    | 0.005 | −0.008–−0.011 | 0.727       |
| Cognitive impaired (117) | Zhang EN  | −0.004   | 0.008 | −0.019–−0.011 | 0.568       |
|                | Zhang BLUP | −0.008   | 0.007 | −0.021–−0.006 | 0.264       |
|                | Hannum    | −0.013   | 0.006 | −0.025–−0.000 | 0.043       |
|                | Horvath   | 0.000    | 0.005 | −0.009–−0.010 | 0.920       |
|                | Phenoage  | −0.002   | 0.004 | −0.011–−0.007 | 0.662       |
| Cognitive impaired Aβ+ (34) | Zhang EN  | −0.033   | 0.020 | −0.074–−0.008 | 0.111       |
|                | Zhang BLUP | −0.031   | 0.016 | −0.064–−0.002 | 0.061       |
|                | Hannum    | −0.029   | 0.014 | −0.057–−0.001 | 0.046**     |
|                | Horvath   | 0.005    | 0.011 | −0.018–−0.029 | 0.647       |
|                | Phenoage  | −0.013   | 0.011 | −0.036–−0.011 | 0.268       |
| Cognitive impaired Aβ− (83) | Zhang EN  | −0.002   | 0.009 | −0.019–−0.016 | 0.825       |
|                | Zhang BLUP | −0.002   | 0.008 | −0.018–−0.013 | 0.770       |
|                | Hannum    | −0.011   | 0.008 | −0.027–−0.004 | 0.143       |
|                | Horvath   | −0.004   | 0.006 | −0.015–−0.008 | 0.544       |
|                | Phenoage  | −0.001   | 0.005 | −0.012–−0.009 | 0.802       |

Table 3 ADNI cross-sectional hippocampal volume

ADNI cross-sectional validation results for associations between accelerated ageing (DBAge) hippocampal volume. p values shown represent values before FDR correction. Bolded values with ** represent values that appeared significant

SE standard error, CI 95 95% confidence intervals, P predictor p value of clock used, EN elastic net, BLUP best linear unbiased prediction, Aβ Amyloid-β
was observed between hippocampal volume and accelerated ageing, using the Hannum clock (estimate $= -0.029, \ SE = 0.014, -0.057 - -0.001, \ p = 0.046$; Table 3). No other associations remained significant after FDR correction.

Accelerated biological ageing is associated with longitudinal measures of brain volume

In the whole cohort, nominally significant associations were observed between hippocampal volume (Supplementary Table 10) and ventricle volume (Supplementary Table 11, Additional File 1) and accelerated ageing, using the Hannum Clock. In the Aβ+ cohort, nominally significant associations were observed between hippocampal volume and accelerated ageing, using the Hannum clock (Supplementary Table 10). In the cognitively unimpaired cohort, nominally significant associations were observed between grey matter volume and accelerated ageing, using the Hannum clock (Supplementary Table 10, Additional File 1). However, no significant associations remained after FDR correction.

Discussion

This study aimed to comprehensively investigate several methods of ascertaining DNAm age to determine if accelerated ageing, calculated in two ways (DiffAge and DBAge), is associated with cross-sectional measures of cognition and AD-related neuroimaging phenotypes and if an individual’s current DNAm age is a predictor of longitudinal changes in the brain and cognition. We report no association of accelerated ageing with brain Aβ burden or measures of cognition and there was no evidence to support the hypothesis that an individual’s current DNAm age is a predictor of future changes in either cognition or neuroimaging phenotypes. However, accelerated ageing, when calculated using the Hannum and Phenoage clocks, was associated with cross-sectional measures of hippocampal volume, when assessed across all AIBL participants included. Further analyses showed that accelerated ageing, as determined using the Zhang EN, Hannum and Phenoage clocks, was also associated with hippocampal volume when limited to Aβ+ individuals and likewise when this analysis was further limited to cognitively unimpaired Aβ+ individuals. However, after validation in the ADNI cohort, significant associations between accelerated ageing and hippocampal volume were limited to those derived from the Hannum clock only. In cognitively unimpaired individuals with high brain Aβ burden, a smaller hippocampal volume was observed in individuals with a larger deviation of biological age from chronological age in both the AIBL and the ADNI cohort. This relationship may be driven by an elevated brain Aβ burden (Aβ positive) in combination with an advanced biological age and explains why this relationship is not observed in the Aβ negative cohorts. There is some evidence to substantiate this by Levine et al. [29], in their study in which there was an association with age acceleration and Aβ load. However, it should be noted that this study was performed on post-mortem pre-frontal cortex brain tissue and the results cannot be directly compared. Further research is therefore needed to examine this relationship in more detail.

Whilst not observed in the present study, longitudinal associations between decline in cognition and age acceleration have been previously observed. Results from the Betula study in Sweden demonstrated that episodic memory performance over 15 years was maintained in ageing in those individuals with a lower DNAm age (calculated using the Horvath clock) [49]. This study included a small sample size of 52 participants and a low participant baseline age (55–65 years), both of which may account for the difference in their findings. In a twin study investigating the relationship between age acceleration and cognitive impairment, Vaccarino et al. [50] showed a faster rate of decline in cognition in individuals who had an older DNAm age (calculated using the Horvath clock) relative to their twin, over an average of 11.5 years. Moreover, this study only included men, and it has been demonstrated that men have a greater age acceleration than women [51]. In a recent study, Beydoun et al. [52] found an association between accelerated age and decline in attention and visuospatial/visuoconstruction ability, in men but not women, using the Hannum clock. In contrast to the study presented here, which focussed on the PACC as a measure of global cognitive decline, Beydoun et al. [52] and Degerman et al. [49] used domain specific measures which may not be directly comparable. Additionally, a constraint of their analysis, and likely their findings, was the inclusion of two timepoints for...
the cognitive outcomes of interest, and though they report significant findings, these could be due to random variations in cognitive performance rather than a meaningful decline over time [52]. In the Lothian Birth Cohort, age acceleration (calculated using the Horvath clock) was associated with cross-sectional measures of lower cognition (general fluid type intelligence derived from the Wechsler Adult Intelligence Scale-III[UK]), weaker grip strength and poorer lung function [53]. A lack of longitudinal association may have been caused by the relatively short follow-up time (6 years), where only small changes in cognition occurred [53].

Similar to studies assessing relationships with cognition, there is also a lack of consistency across studies with respect to neuroimaging phenotypes. Further, there is very limited research with regard to the association of accelerated ageing and neuroimaging phenotypes. To our knowledge, this is the first study to uncover an association between age acceleration and reduced hippocampal volume and specifically only in preclinical AD and not with ageing in the absence of disease (brain Aβ). A small number of other studies have investigated the association of age acceleration and neuroimaging measures with varied results. Hodgson et al. [54] observed that with increasing age acceleration (calculated using the Horvath clock), white matter integrity, both locally and within specific regions of the brain, decreased. Similarly, Hillary et al. [55] observed that higher DNA methylation age (calculated using the GrimAge clock) was significantly associated with decreased overall brain volume (white and grey matter) and increased white matter hyperintensities. In the current study, nominally significant associations between age acceleration and an increase in ventricle volume were observed in the AIBL cohort, which is indicative of an overall smaller brain volume. Levine et al. [29] demonstrated that age acceleration was associated with diffuse plaques, neuritic plaques, Aβ burden and a trend towards an association with neurofibrillary tangles. Chouliaras et al. [56] utilised the Whitehall II imaging sub-study and observed a significant association between accelerated age (calculated using the Hannum clock) and MRI measures; global measure of fractional anisotropy and decreased mean diffusivity, which appeared to be in the opposite direction of similar studies [57]. As is evident, it is hard to compare the results of studies that investigate associations with age acceleration due to a lack of consistency in the availability of data between cohorts, as well as study design, outcomes of interest and clock choice. As such, very few findings have been replicated across more than one study, which increases the potential of false positive findings being published [58].

Finally, the limited findings across studies might be reflective of the limitations of the existing clocks themselves. It should be noted that whilst epigenetic clocks are good at predicting age, there is some evidence to suggest that bespoke clocks that are more disease and/or outcome/phenotype-specific would be better suited for assessing pathological changes and disease progression in unavailable tissue, such as the brain [59, 60]. For example, Grodstein et al. compared the performance of an epigenetic clock trained in cortex to clocks trained in blood, with stronger associations present across all outcomes of interest in the clock trained in brain tissue [60]. Similarly, Porter et al. demonstrated that in clocks trained in specific tissues, the CpG sites included often lead to poor predictive capabilities in other tissues [59]. However, one of the overarching aims of the current study was to assess if markers in peripheral blood are truly reflective of the same changes as those which are observed in the brain and if blood has the potential to be utilised as a surrogate tissue, as obtaining the tissue of interest, regardless of its performance, is not always feasible. The results presented in this study are robust and provide evidence that supports the role of epigenetic clocks in identifying AD-related phenotypes; however, further research, for example into the efficacy of phenotypic specific epigenetic ‘clocks’ or profiles, is warranted.

Limitations

A limitation of this study is that our age acceleration measures were derived from DNA extracted from whole blood and not brain tissue. However, it has previously been demonstrated that age-related DNA changes are conserved across tissue and cell types [11, 61]. Additionally, it is evidenced in several disorders including Huntington’s disease [22], Down syndrome [16] and HIV infections [19] that age acceleration can be observed in both blood and brain tissue. Furthermore, there is a strong correlation between epigenetic profiles of different tissues sampled from
the same individual, with the observed correlation between blood and brain methylation being higher than the correlation for gene expression [11, 61]. This study was performed in the AIBL cohort and validated in the ADNI cohort, both of which are representative of a predominantly Caucasian population. As such, these findings should be replicated in ethnically diverse cohorts to determine whether the methods are applicable to more generalised populations. As well, due to the voluntary nature of the AIBL and ADNI studies, the outcome are cohorts that are highly educated, and any observations made here might not be observed in general populations. Additionally, within the cohorts, there is an overrepresentation of samples collected in the later stages of life, and with this, there is a relatively narrow age range at the higher age spectrum. This has previously been observed to potentially influence the calculation of age estimates, specifically through the underestimation of age [62–64]. Even though the EPIC chip is currently the most comprehensive array chip available, it only assesses ~ 3% of CpG sites within the genome, it is possible that the CpGs present do not probe some of the most biologically informative sites. As well, the more biologically informative CpG sites may have not been selected by the modelling algorithms as they did not correlate well with chronological age.

Conclusion

This study is one of only a few which has examined cross-sectional and longitudinal changes in cognitive function and the neuroimaging phenotypes of volumetric MRI and Amyloid-β PET as a function of age acceleration. Further, it is the first to assess and compare multiple methodologies for the calculation of age acceleration in two well-characterised longitudinal ageing cohorts. Although we were only able to identify an association of age acceleration with cross-sectional hippocampal volume, our study is strengthened by the use of a comprehensive set of epigenetic clocks, derived using the best genome-wide DNA methylation array currently available. Our results contribute to a growing literature that supports the role of epigenetic modifications in ageing and Alzheimer’s disease-related phenotypes. Due to their potentially reversible nature, epigenetic modifications may provide a powerful means for a therapeutic target and prevention and intervention strategies in ageing and age-related diseases, such as Alzheimer’s disease.

Acknowledgements

We thank all the investigators within the AIBL who contributed to the design and implementation of the resource and/or provided data but did not actively participate in the development, analysis, interpretation or writing of this current study. A complete listing of AIBL investigators can be found at https://aibl.csiro.au/about/aibl-research-team/.

Australian Imaging, Biomarkers and Lifestyle (AIBL) Study

Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL) funded by the Commonwealth Scientific and Industrial Research Organisation (CSIRO). The AIBL investigators, unless listed, contributed data but did not participate in analysis or writing of this report. AIBL researchers are listed at www.aibl.csiro.au.

Christopher Fowler1, Stephanie R. Rainey-Smith14,15,16, Sabine Bird14, Julia Bomke2, Pierrick Bourget1, Belinda M. Brown15, Samantha C. Burnham1, Ashley I. Bush11, Carolyn Chadunow11, Steven Collins11, James Doecke1,15, Vincent Dore5,6, Kathryn A. Ellis11,17,18, Lisa Evered18, Amir Fazlollahi6, Jurgen Fripp5, Samantha L. Gardener14, Simon Gibson2, Robert Grenfell1, Elise Harrison11, Richard Head6, Liang Jin11,18, Adrian Kamer11, Fiona Lamb6, Nicola T. Lautenschlager7, Simon M. Laws1,2,2, Qiao-Xin Li11, Lucy Lim1,4, Yen Ying Lim8,11, Andrea Louey11, S. Lance Macaulay3, Lucy Mackintosh19, Ralph N. Martins14,20, Paul Marutz11,12, Colin L. Masters11, Simon McBride3, Lidija Milicic1,2, Kelly Pertile11, Tenielle Porter1,2,4, Morgan Radler11, Joanne Robertson11, Mark Rodrigues14, Christopher C. Rowe6,11, Rebecca Rumble11, Olivier Salvado21, Greg Savage22, Rosita Shishegar5,8, Brendan Silbert19, Magdalene Soh14, Hamid R. Sohrabi15,20, Kevin Taddei1,2, Christine Thai11, Brett Trounson11, Regan Tyrrell4, Michael Vacher1,2,3, Shiji Varghese11,18, Victor L. Villemagne1,6,13, Michael Weinborn14,15, Michael Woodward13, Ying Xia1, David Ames1,11,18,24

1Centre for Precision Health, Edith Cowan University, Joondalup 6027, Western Australia. 2Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia. 3CSIRO Health and Bioscience, Australian e-Health Research Centre, Floreat 6014, Western Australia. 4School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, 6102, Western Australia. 5Australian e-Health Research Centre, CSIRO, Parkville 3052, Victoria, Australia. 6Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia. 7Australian e-Health Research Centre, CSIRO, Herston 4029, Queensland, Australia. 8School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia. 9Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, VIC, Australia. 10Cogstate Ltd, Melbourne, VIC, Australia. 11Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. 12School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia. 13Murdoch
University, Murdoch, WA, Australia. 16School of Psychological Science, University of Western Australia, Crawley, WA, Australia. 17University of Melbourne Academic Unit for Psychiatry of Old Age, Parkville, VIC, Australia. 18Melbourne School of Psychological Sciences, Melbourne, VIC, Australia. 19Department of Anaesthesia and Acute Pain Medicine, St Vincent’s Hospital Melbourne, Victoria Parade, Fitzroy, VIC, Australia. 20Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia. 21CSIRO Data61, Brisbane, QLD, Australia. 22Department of Psychology, Macquarie University, Sydney, NSW, Australia. 23Department of Geriatric Medicine Austin Hospital, Heidelberg, VIC, Australia. 24National Ageing Research Institute (NARI), Parkville, VIC, Australia.

Alzheimer’s Disease Neuroimaging Initiative (ADNI)#

# Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Michael Weiner25, Paul Aisen26, Ronald Petersen27, Clifford R. Jack Jr27, William Jagust28, John Q. Trojanowski29, Arthur W. Toga30, Laurel Beckett31, Robert C. Green32, Andrew J. Saykin33, John C. Morris30, Leslie M. Shaw29, Enchi Liu34, Tom Monte35, Ronald G. Thomas36, Michael Donohue37, Sarah Walter26, Devon Gessert38, Tamie Sather26, Gus Jimenez39, Danielle Harvey38, Matthew Bernstein39, Nick Fox40, Paul Thompson37, Norbert Schuff34, Charles DeCari31, Bret Borowski41, Jeff Gunter37, Matt Senjem37, Prashanthi Venuri35, David Jones27, Kejal Kantarci27, Chad Ward27, Robert A. Koepp42, Norm Foster35, Eric M. Reiman37, Kewei Chen41, Chet Mathis42, Susan Landau26, Nigel J. Cairns43, Erin Householder44, Lisa Taylor Reinwald45, Virginia Lee44, Magdalena Korecka46, Michal Figurski47, Karen Crawford48, Scott Neu49, Tatiana M. Foroud50, Steven Potkin51, Li Shen33, Faber Kelley52, Sungeun Kim53, Kwangso Nho54, Zaven Kachaturian55, Richard Frank56, Peter J. Snyder57, Susan Molchan58, Jeffrey Kaye59, Joseph Quinn60, Betty Ding61, Raina Carter26, Sara Dolen52, Lon S. Schneider53, Sonia Pawluczky53, Mauricio Becerra60, Libertad Teodoro60, Bryan M. Spann30, James Brewer62, Helen Vanderswag62, Adam Fleisher63, Judith L. Heidebrink64, Joanne L. Lord65, Ronald Petersen27, Sara S. Mason27, Colleen S. Albers66, David Knopman67, Kris Johnson68, Rachelle S. Doody69, Michael Vila-lanueva Mey60, Munir Chowdhury61, Susan Rountree62, Mimi Dang63, Yaakov Stern64, Lawrence S. Honig65, Karen L. Bell66, Beau Ances67, Maria Carroll68, Sue Leon69, Erin Householder43, Mark A. Mintun70, Stacy Schneider43, Angela Oliver-Ng71, Randall Griffith72, David Clark72, David Geldmacher73, John Brockington74, Erik Roberson75, Hillel Grossman76, Effie Mitsis77, Leyla deToledo-Morrell78, Raj C. Shah79, Ranjan Duara80, Daniel Varon81, Maria T. Greig82, Peggy Roberts82, Marilyn Albert83, Chiadi Onyike84, Daniel D’Agostino II85, Stephanie Kelb78, James E. Galvin86, Dana M. Pogoreles87, Brittany Cerbone88, Christina A. Michel89, Henry Rusinek90, Moy J. de Leon91, Lidia Glodzik92, Susan De Santi93, P. Murali Doraiswamy94, Jeffrey R. Petrella95, Terence Z. Wong96, Steven E. Arnold97, Jason H. Karlawish98, David A. Wolk99, Charles D. Smith60, Greg Jicha60, Peter Hardy60, Partha Sinha60, Elizabeth Oates60, Gary Conard60, Oscar L. Lopez62, MaryAnn Oakley62, Donna M. Simpson62, Anton P. Porsteinsson63, Bonnie S. Goldstein63, Kim Martin64, Kelly M. Makino65, M. Saleem Ismaiel66, Connie Brand67, Ruth A. Mulnard68, Gaby Thai69, Catherine Mc Adams Ortiz70, Kyle Womack62, Dana Mathews62, Mary Quiceno72, Ramon Diaz Arrastia72, Richard King72, Myron Weiner72, Kristen Martin Cook73, Michael DeVoues74, Allan I. Levey75, James J. Lah76, Janet S. Cellar77, Jeffrey M. Burns78, Heather S. Anderson79, Russell H. Swardlow80, Lianna Apostolova81, Kathleen Tingus82, Ellen Woo83, Daniel H. S. Silverman83, Po H. Lu84, George Bartozsk65, Neil R. Graff Radford86, Francine Parfit66, Tracy Kendall83, Heather Johnson87, Martin R. Farlow88, Ann Marie Hake89, Brandy R. Matthews38, Scott Herrig90, Cynthia Hunt91, Christopher H. van Dyck92, Richard E. Carson93, Martha G. MacAvoy94, Howard Chertkow95, Howard Bergman96, Chris Housein97, Sandra Black98, Bojana Stefanovic98, Curtis Caldwell99, Ging Yuek Robin Hsiung72, Howard Feldman73, Benita Mudge74, Michele Assaly Past75, Andrew Kertzes72, John Rogers76, Dick Trost77, Charles Berrick78, Donna Munic79, Diana Kerwin79, Marek Marsel Mesulam79, Kristine Lipowski80, Chuang Kuo Wu80, Nancy Johnson81, Carl Sadowsky81, Walter Martinez82, Teresa Villena83, Raymond Scott Turner84, Kathleen Johnson85, Brigid Reynolds85, Reisa A. Sperling86, Keith A. Johnson87, Gad Marshall85, Meghan Frey88, Jeromeyesavage89, Joy L. Taylor90, Barton Lane91, Allyson Rosen92, Jared Tinklenberg93, Marwan N. Sabbagh94, Christine M. Belden95, Sandra A. Jacobson96, Sherey A. Sirrel97, Neil Kovall98, Ronald Killiany99, Andrew E. Budson80, Alexander Norbash81, Patricia Lynn Johnson82, Thomas O. Obisesan82, Saba Wolday83, Joanne Allard84, Alan Lerner80, Paula Ogrocki85, Leon Hudson86, Evan Fletcher87, Owen Carmichael88, John Olichney89, Charles DeCarli89, Smita Kittur82, Michael Borrie83, T. Y. Lee84, Rob Bartha85, Sterling Johnson86, Sanjay Asthana86, Cynthia M. Carlsson87, Steven G. Potkin88, Adrián Preda81, Dana Nguyen85, Pierre Tariot81, Adam Fleisher81, Stephanie Reeder82, Vernon Bates86, Horacio Capote87, Michelle Rainka88, Douglas W. Scharre89, Maria Katakis89, Anahtia Adeli90, Earl A. Zimmerman91, Dzintra Celmins92, Alice D. Brown93, Godfrey D. Pearson94, Karen Blank95, Karen Andersen96, Robert B. Santulli97, Tamar J. Kitzmiller98, Eben S. Schwartz99, Kaycee M. Sinks99, Jeff D. Williamson91, Predeap Garg91, Franklin Watkins91, Brian R. Ott92, Henry Querfurth93, Geoffrey Tremont92, Stephen Salloway93, Paul Malloy93, Stephen Correia93, Howard J. Rosen94, Bruce L. Miller95, Jacobo Mintzer96, Kenneth Spicer97, David Bachman97, Elizabeth Finger98, Stephen Pasternak97, Irina Rachinsky98, John Rogers99, Andrew Kertzes100, Dick Drost101, Nunzio Pomara102, Raymundo Hernandez103, Antero Sarrael104, Susan K. Schultz105, Laura L. Boles Ponto106, Hyungsub Shim107, Karen Elizabeth Smith108, Norman Relkin109, Gloria Chaing110, Lisa Raudin111, Amanda Smith109, Kristin Fargher109 & Balebail Ashok Raj110.

25UC San Francisco, San Francisco, CA, USA. 26University of California San Diego, San Diego, CA, USA. 27Mayo Clinic, Rochester, NY, USA. 28UC Berkeley, Berkeley, CA, USA. 29University of Pennsylvania, Philadelphia, PA, USA. 30University of Southern California, Los Angeles, CA, USA. 31UC Davis, Davis, CA, USA. 32Birgham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. 33Indiana
University, Bloomington, IND, USA. 31Janssen Alzheimer Immunotherapy, South San Francisco, CA, USA. 32University of Washington, Seattle, WA, USA. 33University of London, London, UK. 34UCSF School of Medicine, Los Angeles, CA, USA. 35UCSF MRI, San Francisco, CA, USA. 36University of Michigan, Ann Arbor, MI, USA. 37University of Utah, Salt Lake City, UT, USA. 38BANNER Alzheimer’s Institute, Phoenix, AZ, USA. 39University of Pittsburgh, Pittsburgh, PA, USA. 40Washington University St Louis, St Louis, MO, USA. 41UPenn School of Medicine, Philadelphia, PA, USA. 42University of California, Irvine, CA, USA. 43Washington University, St Louis, St Louis, MO, USA. 44University of Wisconsin, Madison, WI, USA. 45University of Michigan, Ann Arbor, MI, USA. 46University of Utah, Salt Lake City, UT, USA. 47Banner Alzheimer’s Institute, Phoenix, AZ, USA. 48University of Pittsburgh, Pittsburgh, PA, USA. 49Washington University St Louis, St Louis, MO, USA. 50Oregon Health and Science University, Portland, OR, USA. 51Baylor College of Medicine, Houston, TX, USA. 52Columbia University Medical Center, New York, NY, USA. 53University of Alabama Birmingham, Birmingham, MO, USA. 54Mount Sinai School of Medicine, New York, NY, USA. 55Rush University Medical Center, Chicago, IL, USA. 56Wien Center, Vienna, Austria. 57Johns Hopkins University, Baltimore, MD, USA. 58New York University, New York, NY, USA. 59Duke University Medical Center, Durham, NC, USA. 60University of Kentucky, Lexington, KY, USA. 61University of Rochester Medical Center, Rochester, NY, USA. 62University of Texas Southwestern Medical School, Dallas, TX, USA. 63Emory University, Atlanta, GA, USA. 64University of Kansas Medical Center, Lawrence, KS, USA. 65University of California, Los Angeles, CA, USA. 66Mayo Clinic, Jacksonville, FL, USA. 67Yale University School of Medicine, New Haven, CT, USA. 68McGill Univ., Montreal Jewish General Hospital, Montreal, WI, USA. 69Sunnybrook Health Sciences, Toronto, ON, Canada. 70U.B.C. Clinic for AD & Related Disorders, British Columbia, BC, Canada. 71Cognitive Neurology St. Joseph’s, Toronto, ON, Canada. 72Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA. 73Northwestern University, Evanston, IL, USA. 74Premiere Research Inst Palm Beach Neurology, West Palm Beach, FL, USA. 75Georgetown University Medical Center, Washington, DC, USA. 76Stanford University, Santa Clara County, CA, USA. 77Banner Sun Health Research Institute, Sun City, AZ, USA. 78Boston University, Boston, MA, USA. 79Howard University, Washington, DC, USA. 80Case Western Reserve University, Cleveland, OH, USA. 81University of California, Davis Sacramento, CA, USA. 82Neurological Care of CNY, New York, NY, USA. 83Parkwood Hospital, Parkwood, CA, USA. 84University of Wisconsin, Madison, WI, USA. 85University of California, Irvine BIC, Irvine, CA, USA. 86Dent Neurologic Institute, Amherst, MA, USA. 87Ohio State University, Columbus, OH, USA. 88Albany Medical College, Albany, NY, USA. 89Hartford Hosp, Olin Neuropsychiatry Research Center, Hartford, CT, USA. 90Dartmouth Hitchcock Medical Center, Albany, NY, USA. 91Wake Forest University Health Sciences, Winston-Salem, NC, USA. 92Rhode Island Hospital, Providence, RI, USA. 93Butler Hospital, Providence, RI, USA. 94Medical University South Carolina, Charleston, SC, USA. 95St. Joseph’s Health Care, Toronto, ON, Canada. 96Cognitive Neurology St. Joseph’s, Toronto, ON, Canada. 97Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA. 98University of South Florida: USF Health Byrd Alzheimer’s Institute, Tampa, FL, USA.

Author contribution  TP, SCB, VLV and SML designed the study. LM performed the main analyses. MV, TP, VD, SCB, PB, RS, JD, NJA, RT, PM, CCR, VLV and SML performed preliminary analyses and/or collected or helped with curation of genetic, epigenetic or phenotypic data. TP, VD, SCB, PM, CLM, VLV and SML provided input on the interpretation of results. LM drafted the manuscript with contributions from MV, TP and SML. All authors read, commented and approved the final manuscript.

Funding  Open Access funding enabled and organized by CAUL and its Member Institutions Funding for the AIBL study was provided in part by the study partners (Commonwealth Scientific Industrial and research Organisation (CSIRO), Edith Cowan University (ECU), Mental Health Research Institute (MHRI), National Ageing Research Institute (NARI), Austin Health, CogState Ltd.). The AIBL study has also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as funding from the Science and Industry Endowment Fund (SIEF) and the Cooperative Research Centre (CRC) for Mental Health—funded through the CRC Program, an Australian Government Initiative. Funding for this research was also supported through a NHMRC grant (GNT1161706) awarded to SML. Some of the DNAm data were generated by funding by the from the National Health and Medical Research Council (NHMRC) Boosting Dementia Research Grant (1151854) linked to the Joint Programming for Neurodegenerative Disease (JPND) BRAIN-MEND grant awarded to NA, SML. These data are available from the GEO repository accession number GSE153712.

Data availability  All AIBL data, and that specific to this study, is publicly accessible to all interested parties through an Expression of Interest procedure and is governed by the AIBL Data Use Agreement (aibl.csiro.au/awd). AIBL DNAm data are available from the GEO repository accession number GSE153712. All data derived from the ADNI cohort, and that specific to this study, are available to researchers by request as outlined in the ADNI access policy (adni.loni.usc.edu).

Declarations  

Ethics approval and consent to participate  Informed written consent was given by all volunteers, and ethics approvals have been granted by the institutional ethics committees of Austin Health, St. Vincent’s Health, Hollywood Private Hospital and Edith Cowan University for the AIBL study. The institutional review boards of all participating ADNI sites reviewed and approved the data collection protocols provided by ADNI.

Consent for publication  Not applicable.

Competing interests  The authors declare no competing interests.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217.
2. Zampieri M, Ciccione F, Calabrese R, Franceschi C, Bürkle A, Caiafa P. Reconfiguration of DNA methylation in aging. Mech Ageing Dev. 2015;151:60–70.
3. Xiao F-H, Kong Q-P, Perry B, He Y-H. Progress on the role of DNA methylation in aging and longevity. Brief Funct Genom. 2016;15(6):454–9.
4. Christiansen L, Lenart A, Tan Q, Vaupel JW, Aviv A, McGue M, et al. DNA methylation age is associated with mortality in a longitudinal Danish twin study. Aging Cell. 2016;15(1):149–54.
5. Bell CG, Xia Y, Yuan W, Gao F, Ward K, Roos L, et al. Novel regional age-associated DNA methylation changes within human common disease-associated loci. Genome Biol. 2016;17(1):193.
6. Rakyan VK, Down T, Maslau S, Andrew T, Yang T-P, Beyan H, et al. Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. Genome Res. 2010;20(4):434–9.
7. Spiers H, Hannon E, Wells S, Williams B, Fernandez C, Mill J. Age-associated changes in DNA methylation across multiple tissues in an inbred mouse model. Mech Ageing Dev. 2016;154:20–3.
8. Bell CG, Lowe R, Adams PD, Baccarelli AA, Beck S, Bell JT, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 2019;20(1):249.
9. Bocklandt S, Lin W, Sehl ME, Sánchez FJ, Sinhiser JS, Horvath S, et al. Epigenetic predictor of age. PLoS ONE. 2011;6(6):e14821.
10. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49(2):359–67.
11. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.
12. Zhang Q, Vallerga CL, Walker RM, Lin T, Henders AK, Montgomery GW, et al. Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. Genome Med. 2019;11(1):54.
13. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573–91.
14. Jiang S, Guo Y. Epigenetic clock: DNA methylation in aging. Stem Cells Int. 2020;2020:1047896.
15. McCartney DL, Stevenson AJ, Walker RM, Gibson J, Morris SW, Campbell A, et al. Investigating the relationship between DNA methylation age acceleration and risk factors for Alzheimer’s disease. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:429–37.
16. Horvath S, Garagnani P, Bacalini MG, Pirazzini C, Salvioli S, Gentilini D, et al. Accelerated epigenetic aging in Down syndrome. Aging Cell. 2015;14(3):491–5.
17. Maierhofer A, Flunkert J, Oshima J, Martin GM, Haaf T, Horvath S. Accelerated epigenetic aging in Werner syndrome. Aging. 2017;9(4):1143–52.
18. Gross AM, Jaeger PA, Kreisberg JF, Licon K, Jepsen KL, Khosroheidari M, et al. Methylyme-wide analysis of chronic HIV infection reveals five-year increase in biological age and epigenetic targeting of HLA. Mol Cell. 2016;62(2):157–68.
19. Horvath S, Levine AJ. HIV-1 infection accelerates age according to the epigenetic clock. J Infect Dis. 2015;212(10):1563–73.
20. Quach A, Levine ME, Tanaka T, Lu AT, Chen BH, Ferrucci L, et al. Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. Aging. 2017;9(2):419–46.
21. Horvath S, Ritz BR. Increased epigenetic age and granulocyte counts in the blood of Parkinson’s disease patients. Aging. 2015;7(12):1130–42.
22. Horvath S, Langfelder P, Kwak S, Aaronson J, Rosinski J, Vogt TF, et al. Huntington’s disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. Aging. 2016;8(7):1485–512.
23. Roubroeks JA, Smith RG, van den Hove DL, Lunnon K. Epigenetics and DNA methylation profiling in Alzheimer’s disease and other neurodegenerative diseases. J Neurochem. 2017;143(2):158–70.
24. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, et al. Alzheimer’s disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17(9):1156–63.
25. Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, Volta M, et al. Methylyme profiling implicates cortical deregulation of ANK1 in Alzheimer’s disease. Nat Neurosci. 2014;17(9):1164–70.
26. Watson CT, Roussos P, Garg P, Ho DJ, Azam N, Katsel PL, et al. Genome-wide12 DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures associated with Alzheimer’s disease. Genome Med. 2016;8:5.
27. Zhao J, Zhu Y, Yang J, Li L, Wu H, De Jager PL, et al. A genome-wide profiling of brain DNA hydroxymethylation in Alzheimer’s disease. Alzheimers Dement. 2017;13(6):674–88.
28. Fransquet PD, Lacaze P, Saffery R, McNeil J, Woods R, Ryan J. Blood DNA methylation as a potential biomarker of dementia: a systematic review. Alzheimers Dement. 2018;14(1):81–103.
29. Levine ME, Lu AT, Bennett DA, Horvath S. Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer’s disease related cognitive functioning. Aging. 2015;7(12):1198–211.
30. Starnawaska A, Tan Q, Lenart A, McGue M, Mors O, Borglum AD, et al. Blood DNA methylation age is not associated with cognitive functioning in middle-aged monozygotic twins. Neurobiol Aging. 2017;50:60–3.
31. Belsky DW, Moffitt TE, Cohen AA, Corcoran DL, Levine ME, Prinz JA, et al. Eleven telomere, epigenetic clock, and biomarker-composite quantifications of biological aging: do they measure the same thing? Am J Epidemiol. 2018;187(6):1220–30.
32. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr. 2009;21(4):672–87.
33. Fowler C, Rainey-Smith SR, Bird S, Bomke J, Bourgeat P, Brown BM, et al. Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer’s disease. J Alzheimers Dis Rep. 2019;5(1):S159-66.
34. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15(4):869–xii.
35. Bourgeat P, Vilmagne VL, Dore V, Brown B, Macaulay SL, Martins R, et al. Comparison of MR-les PiB SUVr quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159-66.
36. Bourgeat P, Doré V, Fripp J, Ames D, Masters CL, Salvador O, et al. Implementing the centroid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL. Neuroimage. 2018;183:387–93.
37. Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, et al. Utilizing the Centoid scale in cross-sectional and longitudinal PiB PET studies. Neuro Image Clin. 2018;19:406–16.
38. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961–70.
39. Insel PS, Weiner M, Mackin RS, Mormino E, Lim YY, Stomrud E, et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology. 2019;93(4):e322.
40. Porter T, Vilmagne VL, Savage G, Milicic L, Ying Lim Y, Maruff P, et al. Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer’s disease. Pers Med Psych. 2018;7–8:14–20.
41. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neurology. 2010;74(3):201.
42. Nabais MF, Laws SM, Lin T, Vallerga CL, Armstrong NJ, Blair IP, et al. Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biol. 2021;22(1):90.
43. Min JL, Hemani G, Davey Smith G, Relton C, Suderman M. Meffil: efficient normalization and analysis of very large DNA methylation datasets. Bioinformatics. 2018;34(23):3983–9.
44. Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai P-C, et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. Aging. 2016;8(9):1844–65.
45. Declerck K, Vanden BW. Back to the future: epigenetic clock plasticity towards healthy ageing. Mech Ageing Dev. 2018;174:18–29.
46. Benjamin Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57(1):289–300.
47. Lee KWK, Pausova Z. Cigarette smoking and DNA methylation. Front Genet. 2013;4:132.
48. Akae H. A new look at the statistical model identification. In: Parzen E, Tanabe K, Kitagawa G, editors. Selected Papers of Hirotugu Akaike. New York: Springer New York; 1998. p. 215–22.
49. Degerman S, Josefsson M, Nordin Adolphson A, Wennstedt S, Landfors M, Haider Z, et al. Maintained memory in aging is associated with young epigenetic age. Neurobiol Aging. 2017;55:167–71.
50. Vaccarino V, Huang M, Wang Z, Hui Q, Shah AJ, Goldberg J, et al. Epigenetic age acceleration and cognitive decline: a twin study. J Gerontol A Biol Sci Med Sci. 2021;76(10):1854–63.
51. Horvath S, Guven M, Levine ME, Trumble BC, Kaplan H, Allayee H, et al. An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol. 2016;17(1):171.
52. Beydoun MA, Shaked D, Tajuddin SM, Weiss J, Evans MK, Zonderman AB. Accelerated epigenetic age and cognitive decline among urban-dwelling adults. Neurology. 2020;94(6):e613–25.
53. Marioni RE, Shah S, McRae AF, Ritchie SJ, Muniz-Terrera G, Harris SE, et al. The epigenetic clock is correlated with physical and cognitive fitness in the Lothian Birth Cohort 1936. Int J Epidemiol. 2015;44(4):1388–96.
54. Hodgson KG, Carless MA, Kulkarni H, Curran JE, Sprooten E, Knowles EE, et al. Epigenetic age acceleration assessed with human white-matter images. J Neurosci. 2017;37(18):4735–43.
55. Hillary RF, Stevenson AJ, Cox SR, McCartney DL, Harris SE, Seboth A, et al. An epigenetic predictor of death captures multi-modal measures of brain health. Mol Psychiatry. 2021;26(8):3806–16.
56. Chouliares L, Pshiva E, Haapakoski R, Zseldos E, Mahmood A, Filippini N, et al. Peripheral DNA methylation, cognitive decline and brain aging: pilot findings from the Whitehall II imaging study. Epigenomics. 2018;10(5):585–95.
57. Mak E, Gabel S, Mirette H, Su L, Williams GB, Waldman A, et al. Structural neuroimaging in preclinical dementia: from microstructural deficits and grey matter atrophy to macroscale connectomic changes. Ageing Res Rev. 2017;35:250–64.
58. Fransquet PD, Ryan J. The current status of blood epigenetic biomarkers for dementia. Crit Rev Clin Lab Sci. 2019;56(7):435–57.
59 Porter HL, Brown CA, Roopnarinesingh X, Giles CB, Georgescu C, Freeman WM, et al. Many chronological aging clocks can be found throughout the epigenome: implications for quantifying biological aging. Aging Cell. 2021;20(11):e13492.

60. Grodstein F, Lemos B, Yu L, Klein H-U, Iatrou A, Buchman AS, et al. The association of epigenetic clocks in brain tissue with brain pathologies and common aging phenotypes. Neurobiol Dis. 2021;157:105428.

61. Horvath S, Zhang Y, Langfelder P, Kahn RS, Boks MPM, van Eijk K, et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 2012;13(10):R97.

62. El Khoury LY, Gorrie-Stone T, Smart M, Hughes A, Bao Y, Andrayas A, et al. Systematic underestimation of the epigenetic clock and age acceleration in older subjects. Genome Biol. 2019;20(1):283.

63. Shireby GL, Davies JP, Francis PT, Burrage J, Walker EM, Neilson GWA, et al. Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex. Brain. 2020;143(12):3763–75.

64. Dhingra R, Kwee LC, Diaz-Sanchez D, Devlin RB, Cacso W, Hauser ER, et al. Evaluating DNA methylation age on the Illumina MethylationEPIC Bead Chip. PLoS ONE. 2019;14(4):e0207834.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.